Gilead Sciences continues to deepen its oncology pipeline, acquiring a 49.9 percent equity interest in Pionyr Immunotherapeutics for $275 million and an exclusive option to buy the rest of the company.
German drugmaker Bayer signed an alliance with Arvinas Inc. to gain access to the U.S. biotech firm’s experimental protein drugs and crop protection technology in a deal worth up to $750 million.
Vertex Pharmaceuticals Incorporated and Genomics plc announced a three-year collaboration (extendable to five years) to use human genetics and machine learning to improve discovery of targets for precision medicines, and to advance understanding of the clinical impact of human genetic variation and patient stratification in diseases with significant unmet need.
